Pheochromocytoma is a catecholamine -producing tumor of the adrenergic system or the chromaffin cells among which approximately 90% are adrenomedullary. Non-adrenal tumors are also found which arise from the sympathetic nervous system. These are designated as extra-adrenal pheochromocytomas or functioning paragangliomas and they most commonly occur in the abdomen, chest and neck. Pheochromocytomas are rare in nature and it occurs in 1 to 2 people out of 100,000 adults.
Symptoms include hypertension (paroxysmal or persistent), headache, pallor, hyperhidrosis, anxiety, tachycardia, palpitations, angina, hyperglycemia, weight loss, paresthesias, visual disturbances (second-degree hypertensive retinopathy), dilated pupils are observed according to the secretions of catecholamines by the tumor. Other than these, events like vasoconstriction can occur due to alpha-adrenergic stimulation, a decrease in insulin secretion is observed by alpha2- adrenergic stimulation. Similarly, cardiac inotropy, bronchodilation, vasodilation and others can be observed. Cardiomyopathy may also be observed due to excessive levels of catecholamines. are toxic to the myocardium and cardiomyopathy may result. The symptoms can be episodic in nature. Paroxysms may last from less than 1 min to several hours and may occur only once every few months or as frequently as multiple times per day.
1. Checking the above-mentioned symptoms is important as the first step of diagnosis. Other than this pressor response to histamine, glucagon, droperidol, tyramine, metoclopramide, saralasin, tricyclic antidepressants, or phenothiazines also indicate the possibility of pheochromocytoma.
2. Patients when examined physically may be observed to be normal apart from the occurrence of paroxysm.
3. In order to confirm through laboratory evaluation plasma or urinary catecholamine levels or urinary catecholamine metabolite (VMA or metanephrine) levels are checked. In rare cases, suppression tests (clonidine) or provocative tests (glucagon) are needed.
4. The levels of plasma and urinary catecholamines can be interfered by stimulation of endogenous catecholamines (e.g., surgery, stroke) or administration of exogenous catecholamines which may include various drugs (alpha2-agonists, methyldopa, converting enzyme inhibitors and others)
5. Tumors may also be localized by scanning techniques like CT, MRI, or venous blood sampling for catecholamines.
6. The differential diagnosis includes the symptoms of malignant hypertension, thyrotoxic crisis, hypertensive response (to stress, surgery, anesthesia) and so on.
Considering the treatment approaches for pheochromocytoma, surgical excision is meant to be the definitive treatment which requires preoperative management in order to determine the surgical outcome. The preoperative goals include controlling blood pressure, providing adequate intravascular volume, treating tachyarrhythmias, treating heart failure and glucose intolerance. Other than these measures like adequate amounts of blood should be available for transfusion in the perioperative period because bleeding is frequently observed, diuretics should be used sparingly as intravascular volume is already constricted by catecholamines, drugs that releases catecholamine are to be avoided. Postoperative monitoring of cardiovascular and metabolic activities are required. Meperidine, and benzodiazepines can be used for sedation and pain. In the case of recurrent hypertension after operation the possibility of residual tumor needs to be checked.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Lesser-known lobular breast cancer on the rise in U.S. women
2.
Study finds that AI is better at forecasting the risk of developing cancer.
3.
Kate Middleton and Remission: Oncologists Weigh In
4.
According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.
5.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
1.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
2.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
3.
Tumor-Specific Fluorescent Peptide Navigation in Surgical Oncology
4.
Digital Blood Cell Morphology Libraries for Longitudinal Hematologic Monitoring
5.
The importance of understanding normal serum osmolality
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
3.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
5.
Best Practices in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation